Doctors say statin side effects strike up to one in five older patients

Statins are the most prescribed cardiovascular drugs in the world, lowering LDL cholesterol and cutting the risk of heart attacks and strokes across tens of millions of patients. Yet the medicines carry a persistent reputation for causing muscle aches, cramps and weakness, and in real-world practice a substantial minority of older patients report exactly those complaints. Surveys of routine care have put the figure as high as roughly one in five. The striking twist is that rigorous blinded trials find the drugs themselves account for only a small fraction of that burden, exposing a wide gap between what patients experience and what the pills can be shown to cause.

What statin-associated muscle symptoms actually are

The complaints grouped under the label statin-associated muscle symptoms range from mild aches and stiffness to weakness and cramps, usually with normal or only slightly raised levels of creatine kinase, the enzyme that signals genuine muscle damage. True statin-induced muscle injury, and the rare, dangerous breakdown of muscle tissue known as rhabdomyolysis, sit at the severe end and are uncommon. Most reports fall into the milder, subjective category that is harder to measure and easy to attribute to the drug. Because muscle aches are also extremely common in older adults for reasons unrelated to any medication, from arthritis to inactivity to ordinary aging, separating drug effect from background noise is the central difficulty in this field.

Where the one-in-five figure comes from

The high estimates trace to observational data rather than controlled experiments. A consensus statement from the European Atherosclerosis Society, published in the European Heart Journal, reported that muscle symptoms turn up in roughly 7 to 29 percent of patients across registries and observational studies, a band whose upper reaches include something close to a fifth or more of users. Those numbers come from patients who know they are taking a statin and who are often reporting symptoms in clinics where the drug’s reputation precedes it. That context matters, because expectation shapes perception, and the same complaint can be logged very differently depending on whether a patient and doctor are primed to suspect the medicine.

The verdict from blinded trials

When patients do not know whether they are receiving a statin or a placebo, the picture changes sharply. A large individual participant data meta-analysis of randomized trials, published in The Lancet, found that statins produced only about a 7 percent relative increase in reports of muscle pain or weakness during the first year, corresponding to a small absolute excess. By that accounting, only about one in 15 muscle complaints among people taking a statin was actually attributable to the drug, and after the first year the trials detected essentially no difference between statin and placebo groups. In other words, the great majority of aches that patients blame on statins would have occurred anyway, a conclusion that directly contradicts the impression left by uncontrolled clinic data.

The nocebo effect and n-of-1 experiments

Bridging the two sets of numbers is the nocebo effect, in which the expectation of a side effect makes a person more likely to notice and report it. Researchers tested this directly with a series of randomized, placebo-controlled n-of-1 trials known as StatinWISE, in which patients who had stopped or were considering stopping their medication because of muscle symptoms cycled through blinded periods of statin and dummy tablets. The results of those n-of-1 trials showed no overall difference in muscle symptoms between the statin and placebo months, and many participants who had been convinced the drug was harming them chose to resume treatment afterward. Similar blinded rechallenge studies have reached the same conclusion: symptoms are real and often distressing, but they arise about as often on placebo as on the active drug.

Why the distinction changes the treatment decision

The gap between reported and drug-attributable symptoms carries real stakes, because stopping a statin over aches that the pill did not cause forfeits genuine protection against heart attacks and strokes. The evidence does not dismiss patients’ experiences, since the discomfort is authentic regardless of its source, but it reframes the response. Clinicians increasingly favor confirming a suspected reaction through a supervised pause and rechallenge, adjusting the dose, switching to a different statin, or trying alternate-day regimens before abandoning the class outright. For older patients, who stand to gain the most from cholesterol control and also report the most muscle complaints, that measured approach is designed to keep the cardiovascular benefit while honestly acknowledging that a large share of the feared side effects reflect the nocebo effect rather than the medicine.

Evaluation also looks for factors that can make genuine toxicity more likely. A high statin dose, impaired kidney or liver function, untreated thyroid disease and interactions with certain antibiotics or antifungal drugs can raise exposure or worsen muscle symptoms. Measuring creatine kinase is most useful when weakness is severe, urine darkens or widespread pain appears, not as a routine answer to every ache. Correcting an interaction or choosing a statin metabolized through a different pathway can preserve treatment without ignoring a potentially serious reaction.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview